Materials and Methods: Fifty-five eyes of 46 patients that were diagnosed with iERM following at least 6 months of glaucoma treatment were retrospectively analyzed and included in the study group. Age and sex matched control group of 60 patients was formed from random consecutive patients who were followed up in the glaucoma unit and had no ERM. A multivariate generalized linear model for adjusted analysis including hypertension, diabetes, pseudophakia, and different kinds of glaucoma medication was used to test the differences between the groups. Logistic regression (LR) analysis was used in the multivariate evaluations of the effects on iERM.

Results: The use of PGAs was significantly higher in iERM group (p = 0.009). The use of Dorzolamide in the iERM group was significantly lower than that in the non-ERM group (p = 0.044). The coexistence of PGA use and systemic hypertension (HT) was significantly higher in the iERM group (p=0.035). The effect of PGAs was found to be statistically significant, and the odds ratio of its effect on iERM was found to be 2.932 (95% confidence intervals: 1.295-6.639, p=0.01) times in the LR analysis.

Conclusions: The use of dorzolamide was significantly higher in the non-ERM group. The use of PGAs was significantly higher in the iERM group. Also, there was a significant relationship between PGAs and iERM formation. Keywords : Idiopathic epiretinal membrane, Glaucoma, Prostaglandin analogues, Dorzolamide